Last 12 months
Inside the activity.
0 purchase rows · 240 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 200 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 31 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 04, 2017 Filed Dec 5, 2017 22:32 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
SaleCommon Stock | 36,585 | $86.18 | $3,152,895.30 |
DisclosureSEC source: 0000059478-17-000239 · wf-form4_151251316307730.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,885 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $85.39 to $86.71. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 04, 2017 Filed Dec 5, 2017 22:35 UTC |
Zulueta Alfonso GSVP & President, Lilly Int'l
|
SaleCommon Stock | 3,532 | $86.00 | $303,752.00 |
DisclosureSEC source: 0000059478-17-000241 · wf-form4_151251332901839.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,048 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2017. Read SEC document |
| December 03, 2017 Filed Dec 5, 2017 22:43 UTC |
Ricks David ADirector · President & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 5,496 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000243 · wf-form4_151251380489040.xml · derivative · entry 6 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,496 shares Expires 2017-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| December 03, 2017 Filed Dec 5, 2017 22:43 UTC |
Ricks David ADirector · President & CEO
|
Tax withholdingCommon Stock | 2,601 | $85.32 | $221,917.32 |
DisclosureSEC source: 0000059478-17-000243 · wf-form4_151251380489040.xml · nonDerivative · entry 2 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,458 Read SEC document |
| December 03, 2017 Filed Dec 5, 2017 22:43 UTC |
Ricks David ADirector · President & CEO
|
Exercise / conversionCommon Stock | 5,496 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000243 · wf-form4_151251380489040.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2017 Filed Dec 5, 2017 22:46 UTC |
Fry Stephen FSVP, HR & Diversity
|
Exercise / conversionRestricted Stock Unit · Derivative | 7,557 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000245 · wf-form4_151251394924382.xml · derivative · entry 4 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,557 shares Expires 2017-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| December 03, 2017 Filed Dec 5, 2017 22:46 UTC |
Fry Stephen FSVP, HR & Diversity
|
Tax withholdingCommon Stock | 3,567 | $85.32 | $304,336.44 |
DisclosureSEC source: 0000059478-17-000245 · wf-form4_151251394924382.xml · nonDerivative · entry 2 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,934 Read SEC document |
| December 03, 2017 Filed Dec 5, 2017 22:46 UTC |
Fry Stephen FSVP, HR & Diversity
|
Exercise / conversionCommon Stock | 7,557 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000245 · wf-form4_151251394924382.xml · nonDerivative · entry 1 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2017 Filed Dec 5, 2017 22:48 UTC |
Zakrowski Donald AChief Accounting Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,281 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000247 · wf-form4_151251408859194.xml · derivative · entry 4 Zakrowski Donald A · CIK 0001561539 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,281 shares Expires 2017-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| December 03, 2017 Filed Dec 5, 2017 22:48 UTC |
Zakrowski Donald AChief Accounting Officer
|
Tax withholdingCommon Stock | 1,070 | $85.32 | $91,292.40 |
DisclosureSEC source: 0000059478-17-000247 · wf-form4_151251408859194.xml · nonDerivative · entry 2 Zakrowski Donald A · CIK 0001561539 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,097 Read SEC document |
| December 03, 2017 Filed Dec 5, 2017 22:48 UTC |
Zakrowski Donald AChief Accounting Officer
|
Exercise / conversionCommon Stock | 3,281 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000247 · wf-form4_151251408859194.xml · nonDerivative · entry 1 Zakrowski Donald A · CIK 0001561539 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 14:44 UTC |
MARRAM ELLEN RDirector
|
GrantCommon Stock | 1,924 | $83.18 | $160,038.32 |
DisclosureSEC source: 0000059478-17-000209 · wf-form4_151136183200926.xml · nonDerivative · entry 1 MARRAM ELLEN R · CIK 0001234124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,071 Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 14:54 UTC |
Bertozzi Carolyn RDirector
|
GrantCommon Stock | 1,763 | $83.18 | $146,646.34 |
DisclosureSEC source: 0000059478-17-000211 · wf-form4_151136243499249.xml · nonDerivative · entry 1 Bertozzi Carolyn R · CIK 0001698766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,763 Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 14:56 UTC |
ESKEW MICHAEL LDirector
|
GrantCommon Stock | 1,924 | $83.18 | $160,038.32 |
DisclosureSEC source: 0000059478-17-000213 · wf-form4_151136258913760.xml · nonDerivative · entry 1 ESKEW MICHAEL L · CIK 0001227734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,811 Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 14:59 UTC |
TAI JACKSON PDirector
|
GrantCommon Stock | 1,924 | $83.18 | $160,038.32 |
DisclosureSEC source: 0000059478-17-000215 · wf-form4_151136276060034.xml · nonDerivative · entry 1 TAI JACKSON P · CIK 0001173275 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,899 Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 15:02 UTC |
PRENDERGAST FRANKLYN GDirector
|
GrantCommon Stock | 802 | $83.18 | $66,710.36 |
DisclosureSEC source: 0000059478-17-000217 · wf-form4_151136295636158.xml · nonDerivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,574 Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 15:10 UTC |
SEIFERT KATHI PDirector
|
GrantCommon Stock | 1,924 | $83.18 | $160,038.32 |
DisclosureSEC source: 0000059478-17-000220 · wf-form4_151136339545854.xml · nonDerivative · entry 1 SEIFERT KATHI P · CIK 0001222893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,217 Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 15:13 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 2,055 | $83.18 | $170,934.90 |
DisclosureSEC source: 0000059478-17-000222 · wf-form4_151136357607163.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,153 Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 15:21 UTC |
Baicker KatherineDirector
|
GrantCommon Stock | 1,924 | $83.18 | $160,038.32 |
DisclosureSEC source: 0000059478-17-000224 · wf-form4_151136406609537.xml · nonDerivative · entry 1 Baicker Katherine · CIK 0001537067 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,923 Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 15:24 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 2,040 | $83.18 | $169,687.20 |
DisclosureSEC source: 0000059478-17-000226 · wf-form4_151136426399711.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,183 Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 15:26 UTC |
Kaelin William G JrDirector
|
GrantCommon Stock | 1,924 | $83.18 | $160,038.32 |
DisclosureSEC source: 0000059478-17-000228 · wf-form4_151136440081892.xml · nonDerivative · entry 1 Kaelin William G Jr · CIK 0001551715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,448 Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 15:30 UTC |
JACKSON JAMEREDirector
|
GrantCommon Stock | 1,924 | $83.18 | $160,038.32 |
DisclosureSEC source: 0000059478-17-000230 · wf-form4_151136462958934.xml · nonDerivative · entry 1 JACKSON JAMERE · CIK 0001601813 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,455 Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 15:34 UTC |
Runge Marschall SDirector
|
GrantCommon Stock | 1,924 | $83.18 | $160,038.32 |
DisclosureSEC source: 0000059478-17-000232 · wf-form4_151136479947502.xml · nonDerivative · entry 1 Runge Marschall S · CIK 0001586197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,283 Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 15:38 UTC |
Fyrwald J ErikDirector
|
GrantCommon Stock | 1,924 | $83.18 | $160,038.32 |
DisclosureSEC source: 0000059478-17-000234 · wf-form4_151136509917238.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,760 Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 16:41 UTC |
HOOVER R DAVIDDirector
|
GrantCommon Stock | 1,924 | $83.18 | $160,038.32 |
DisclosureSEC source: 0000059478-17-000237 · wf-form4_151136887132915.xml · nonDerivative · entry 1 HOOVER R DAVID · CIK 0001186033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,284 Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 17:55 UTC |
Zulueta Alfonso GSVP & President, Lilly Int'l
|
SaleCommon Stock | 2,003 | $83.67 | $167,591.01 |
DisclosureSEC source: 0000059478-17-000206 · wf-form4_151059570795341.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,580 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2017. Read SEC document |
| November 06, 2017 Filed Jan 30, 2018 21:10 UTC |
Rice Derica WEVP-Global Services and CFO
|
GiftCommon Stock | 8,670 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000020 · wf-form5_151734660054829.xml · nonDerivative · entry 4 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 395,903 F2 · balance_after: The share total has been updated to correctly reflect a gift to the reporting person's spouse, which was previously reported. F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| November 03, 2017 Filed Dec 5, 2017 22:32 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
GiftCommon Stock | 15,861 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000239 · wf-form4_151251316307730.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,024 Read SEC document |
| October 30, 2017 Filed Jan 30, 2018 21:10 UTC |
Rice Derica WEVP-Global Services and CFO
|
GiftCommon Stock | 182 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000020 · wf-form5_151734660054829.xml · nonDerivative · entry 3 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 404,573 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| October 27, 2017 Filed Jan 30, 2018 21:06 UTC |
Crowe Maria APresident, Mfg. Operations
|
GiftCommon Stock | 1,187 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000018 · wf-form5_151734640031769.xml · nonDerivative · entry 2 Crowe Maria A · CIK 0001538603 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,269 Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 19:51 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 127 | $85.95 | $10,915.65 |
DisclosureSEC source: 0000059478-17-000197 · wf-form4_150835626828636.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,098 Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 19:53 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 112 | $85.95 | $9,626.40 |
DisclosureSEC source: 0000059478-17-000199 · wf-form4_150835642336616.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,143 Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 18:56 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 205,000 | $86.81 | $17,795,025.00 |
DisclosureSEC source: 0001209191-17-056102 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,275,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.655 to $87.115, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 19:39 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 32,443 | $85.50 | $2,773,714.29 |
DisclosureSEC source: 0001209191-17-054552 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,480,804 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.41 to $85.60, inclusive. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 19:39 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 162,557 | $85.07 | $13,828,886.55 |
DisclosureSEC source: 0001209191-17-054552 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,513,247 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.41 to $85.40, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 20:30 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 132 | $82.52 | $10,892.64 |
DisclosureSEC source: 0000059478-17-000191 · wf-form4_150593943899068.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,971 Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 20:34 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 117 | $82.52 | $9,654.84 |
DisclosureSEC source: 0000059478-17-000193 · wf-form4_150593965992037.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,031 Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 19:42 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 6,483 | $83.32 | $540,170.04 |
DisclosureSEC source: 0001209191-17-053130 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,675,804 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.185 to $83.38, inclusive. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 19:42 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 183,517 | $82.50 | $15,139,601.95 |
DisclosureSEC source: 0001209191-17-053130 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,682,287 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.185 to $83.18, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 17:45 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 180,000 | $81.06 | $14,590,080.00 |
DisclosureSEC source: 0001209191-17-051033 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,865,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.66 to $81.35, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| August 21, 2017 Filed Aug 23, 2017 18:49 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 141 | $77.38 | $10,910.58 |
DisclosureSEC source: 0000059478-17-000185 · wf-form4_150351413899419.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,611 Read SEC document |
| August 21, 2017 Filed Aug 23, 2017 18:56 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 125 | $77.38 | $9,672.50 |
DisclosureSEC source: 0000059478-17-000187 · wf-form4_150351455022837.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,897 Read SEC document |
| July 31, 2017 Filed Aug 1, 2017 14:55 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 3,479 | $83.68 | $291,129.68 |
DisclosureSEC source: 0001209191-17-046854 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,045,804 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.65 to $83.75, inclusive. Read SEC document |
| July 31, 2017 Filed Aug 1, 2017 14:55 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 216,521 | $83.08 | $17,988,348.16 |
DisclosureSEC source: 0001209191-17-046854 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,049,283 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.65 to $83.64, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| July 17, 2017 Filed Jul 18, 2017 18:39 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 131 | $83.64 | $10,956.84 |
DisclosureSEC source: 0000059478-17-000176 · wf-form4_150040317644005.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,470 Read SEC document |
| July 17, 2017 Filed Jul 18, 2017 18:56 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 116 | $83.64 | $9,702.24 |
DisclosureSEC source: 0000059478-17-000178 · wf-form4_150040419211535.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,772 Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 13:58 UTC |
Pusey Leigh AnnSVP, Corp. Affairs & Comm.
|
GrantRestricted Stock Unit · Derivative | 7,256 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000174 · wf-form4_149943590285128.xml · derivative · entry 1 Pusey Leigh Ann · CIK 0001708919 · SVP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,256 Underlying: Common Stock · 7,256 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. F2 · derivative.exercise_date: The restricted stock units vest in three annual installments: 2,394 on July 5, 2018, 2,394 on July 5, 2019, and 2,468 on July 5, 2020. F2 · derivative.expiration_date: The restricted stock units vest in three annual installments: 2,394 on July 5, 2018, 2,394 on July 5, 2019, and 2,468 on July 5, 2020. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 14:16 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 210,000 | $84.43 | $17,730,720.00 |
DisclosureSEC source: 0001209191-17-041545 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,265,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.78 to $84.76, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 15:24 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 215,000 | $83.05 | $17,855,363.00 |
DisclosureSEC source: 0001209191-17-041164 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,475,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.66 to $83.655, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 19:40 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 133 | $82.34 | $10,951.22 |
DisclosureSEC source: 0000059478-17-000168 · wf-form4_149807399114216.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,339 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.